Breast Cancer Clinical Trials 2023

Browse 100 Breast Cancer Medical Studies Across 460 Cities

20 Phase 3 Trial · 1632 Breast Cancer Clinics

Reviewed by Michael Gill, B. Sc.
10 Breast Cancer Clinical Trials Near Me
Top Hospitals for Breast Cancer Clinical Trials
Image of Dana-Farber Cancer Institute in Massachusetts.
Dana-Farber Cancer Institute
Boston
8Active Trials
218All Time Trials for Breast Cancer
1998First Breast Cancer Trial
Image of Beth Israel Deaconess Medical Center in Massachusetts.
Beth Israel Deaconess Medical Center
Boston
7Active Trials
128All Time Trials for Breast Cancer
1994First Breast Cancer Trial
Image of Memorial Sloan Kettering Cancer Center in New York.
Memorial Sloan Kettering Cancer Center
New York
7Active Trials
219All Time Trials for Breast Cancer
1994First Breast Cancer Trial
Image of City of Hope Comprehensive Cancer Center in California.
City of Hope Comprehensive Cancer Center
Duarte
7Active Trials
68All Time Trials for Breast Cancer
1997First Breast Cancer Trial
Image of East Bay Radiation Oncology Center in California.
East Bay Radiation Oncology Center
Castro Valley
7Active Trials
30All Time Trials for Breast Cancer
2002First Breast Cancer Trial
Top Cities for Breast Cancer Clinical Trials
Image of Oakland in California.
Oakland
38Active Trials
Highland General HospitalTop Active Site
Image of Denver in Colorado.
Denver
36Active Trials
Porter Adventist HospitalTop Active Site
Breast Cancer Clinical Trials by Phase of TrialBreast Cancer Clinical Trials by Age Group
< 65 Breast Cancer Clinical Trials
1Active Breast Cancer Clinical Trials
Most Recent Breast Cancer Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
Top Treatments for Breast Cancer Clinical Trials
Treatment Name
Active Breast Cancer Clinical Trials
All Time Trials for Breast Cancer
First Recorded Breast Cancer Trial
Treatment
27
27
1987
Abemaciclib
3
65
2014
Trastuzumab
3
325
2000
pharmacological study
2
35
2000
Imlunestrant
2
3
2021
Recently Completed Studies with FDA Approved Treatments for Breast Cancer
Treatment
Year
Sponsor
Trilaciclib
2021
G1 Therapeutics, Inc.
Pembrolizumab
2021
HiberCell, Inc.
Probiotic
2021
Mayo Clinic
Buzzy(R)
2021
University of Wisconsin, Madison
LY3484356
2021
Eli Lilly and Company
ZN-c5
2020
Zeno Alpha Inc.
Zilovertamab vedotin
2020
VelosBio Inc.
Tiragolumab
2020
Hoffmann-La Roche
Nivolumab
2020
Bristol-Myers Squibb
Surgery
2020
Hoffmann-La Roche

What Are Breast Cancer Clinical Trials?

Breast cancer is a cancer that forms in the cells of breasts. Breast cancer symptoms can vary from swollen lymph nodes to a new lump in the breast or armpit. Breast cancer may spread into the surronding tissues if the disease progresses.

In clinical trials, men and women with all types and stages of breast cancer participate in helping doctors and scientists find better treatment methods and medication. In addition, many researchers are looking at innovative therapeutics to determine if they are safe, effective, or even better than standard treatments.

Why Is Breast Cancer Being Studied Through Clinical Trials?

Recent statistics from 2020 have shown a significant increase in women's breast cancer. In addition, breast cancer is now the most diagnosed type of cancer, with 1 in every 3 women diagnosed.

Clinical studies focus on trying out new drugs (medication), different treatment plans, advanced surgery and radiation methods, and various other types of therapy.

What Are The Types of Treatments Available For Breast Cancer?

A breast cancer diagnosis is confirmed by taking a biopsy of the concerned tissue. How breast cancer is treated varies on its type and stage. These treatments include surgery, chemotherapym hormone therapy, targeted drugs, and immunotherapy, and a combination of these are used to treat breast cancer patients.

What Are Some Recent Breakthrough Clinical Trials For Breast Cancer?

There has been several landmark studies involving breast cancer in recent years. Some of the most notable studies are:

2023: Pembrolizumab Improves Survival in Advanced Triple-Negative Breast Cancer The Institute of Cancerology Strasbourg, Strasbourg, France, found that combining chemotherapy with the immunotherapy medicine pembrolizumab (Keytruda) can extend the lives of certain patients with advanced triple-negative breast cancer. This is significant because, in general, triple-negative breast cancer is more aggressive, harder to cure, and recurring than other forms of the disease.

2023: Enhertu Improves Survival for Metastatic “HER2-Low” Breast Cancer The Memorial Sloan Kettering Cancer Center found that trastuzumab deruxtecan (Enhertu), used for the treatment of HER2-low breast cancers, can prolong the life of the patients by up to 6 months. This is significant because the FDA approved this drug for people who had previously received chemotherapy or had their cancer returned within 6 months of surgery or completion of chemotherapy.

Who Are Some Of The Key Opinion Leaders / Researchers / Institutions Conducting Breast Cancer

Dr. Shanu Modi, M.D

Shanu Modi, M.D is a medical oncologist at Memorial Sloan Kettering Cancer Center. Her research focuses on the clinical development of new breast cancer treatments, emphasizing evaluating targeted biological anticancer drugs.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 27th, 2021

Last Reviewed: September 14th, 2023

References1 Hattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M. An update on emerging drugs in osteosarcoma: towards tailored therapies? Expert Opin Emerg Drugs. 2019 Sep;24(3):153-171. doi: 10.1080/14728214.2019.1654455. Epub 2019 Aug 14. Review. https://pubmed.ncbi.nlm.nih.gov/314019032 Hattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M. An update on emerging drugs in osteosarcoma: towards tailored therapies? Expert Opin Emerg Drugs. 2019 Sep;24(3):153-171. doi: 10.1080/14728214.2019.1654455. Epub 2019 Aug 14. https://pubmed.ncbi.nlm.nih.gov/314019033 Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002 Oct 17;347(16):1233-41. https://pubmed.ncbi.nlm.nih.gov/123938204 Wedam SB, Beaver JA, Amiri-Kordestani L, Bloomquist E, Tang S, Goldberg KB, Sridhara R, Ibrahim A, Kim G, Kluetz P, McKee A, Pazdur R. US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments. J Clin Oncol. 2018 Apr 20;36(12):1225-1231. doi: 10.1200/JCO.2017.74.6917. Epub 2018 Mar 9. https://pubmed.ncbi.nlm.nih.gov/295223615 Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, Parkhurst MR, Yang JC, Rosenberg SA. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014 May 9;344(6184):641-5. doi: 10.1126/science.1251102. https://pubmed.ncbi.nlm.nih.gov/248124036 Perez-Garcia J, Soberino J, Racca F, Gion M, Stradella A, Cortes J. Atezolizumab in the treatment of metastatic triple-negative breast cancer. Expert Opin Biol Ther. 2020 Sep;20(9):981-989. doi: 10.1080/14712598.2020.1769063. Epub 2020 May 25. https://pubmed.ncbi.nlm.nih.gov/324507257 Pérez-García J, Soberino J, Racca F, Gion M, Stradella A, Cortés J. Atezolizumab in the treatment of metastatic triple-negative breast cancer. Expert Opin Biol Ther. 2020 Sep;20(9):981-989. doi: 10.1080/14712598.2020.1769063. Epub 2020 May 25. Review. https://pubmed.ncbi.nlm.nih.gov/324507258 Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015 Jan 1;33(1):13-21. doi: 10.1200/JCO.2014.57.0572. Epub 2014 Aug 4. https://pubmed.ncbi.nlm.nih.gov/250927759 Egger SJ, Chan MMK, Luo Q, Wilcken N. Platinum-containing regimens for triple-negative metastatic breast cancer. Cochrane Database Syst Rev. 2020 Oct 21;10(10):CD013750. doi: 10.1002/14651858.CD013750. https://pubmed.ncbi.nlm.nih.gov/3308402010 Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA; TEXT and SOFT Investigators; International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 Jul 10;371(2):107-18. doi: 10.1056/NEJMoa1404037. Epub 2014 Jun 1. https://pubmed.ncbi.nlm.nih.gov/24881463